Last reviewed · How we verify
MRX-4 co-administered with omeprazole
MRX-4 co-administered with omeprazole is a Small molecule drug developed by MicuRx. It is currently in Phase 1 development.
At a glance
| Generic name | MRX-4 co-administered with omeprazole |
|---|---|
| Sponsor | MicuRx |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MRX-4 co-administered with omeprazole CI brief — competitive landscape report
- MRX-4 co-administered with omeprazole updates RSS · CI watch RSS
- MicuRx portfolio CI
Frequently asked questions about MRX-4 co-administered with omeprazole
What is MRX-4 co-administered with omeprazole?
MRX-4 co-administered with omeprazole is a Small molecule drug developed by MicuRx.
Who makes MRX-4 co-administered with omeprazole?
MRX-4 co-administered with omeprazole is developed by MicuRx (see full MicuRx pipeline at /company/micurx).
What development phase is MRX-4 co-administered with omeprazole in?
MRX-4 co-administered with omeprazole is in Phase 1.